3-叔-丁基-4-甲氧基苯甲醛 | 107430-92-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-叔-丁基-4-甲氧基苯甲醛
• 英文名称: 3-Tert-butyl-4-methoxybenzaldehyde
• CAS: 107430-92-2
• 化学式: C₁₂H₁₆O₂
• mdl: MFCD01104342
• 分子量: 192.25
• InChiKey: KHDRYKVXOFJZGS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  N-Boc-哌嗪 、 3-叔-丁基-4-甲氧基苯甲醛 、 三乙酰氧基硼氢化钠 、 碳酸氢钠 在 溶剂黄146 disodium;carbonate 、 Sodium sulfate-III 作用下， 以 二氯甲烷 为溶剂， 反应 12.0h， 生成 N-(tert-butyloxycarbonyl)-N'-(3-tert-butyl-4-methoxy-benzyl)piperazine
  参考文献：
  名称：

  N,N1 substituted piperazines having combined antiaggregant, anticoagulant and vasodilatory activity, and method for producing same

  摘要：

  本发明涉及一般式（I）的N,N'-取代哌嗪衍生物，其中R1和R2表示线性或支链（C1-C4）烷基，线性或支链（C1-C4）烷氧基，CH3C(═O)O或卤素；n=1-5；m=0-3；Z表示CH2，C═O或SO2；X表示C(═NH)NH2，C(═NH)NHC(═NH)NH2或CH2(CHR3)pCH2SO3H，其中R3表示H，OH，CH3C(═O)O或HOSO2O，p=0-1；G表示低分子量有机或矿物酸，钠，钾或铵阳离子，或水。这些衍生物具有抗聚集、抗凝和扩血管的特性。本发明还涉及一种通过在有机溶剂或水中存在碱的情况下将N-取代哌嗪与羧酰胺酰化剂或其盐，或卤代烷磺酸或其盐反应来制备这些衍生物的方法。这些化合物可用于预防和治疗止血系统疾病。

  公开号：

  US09249115B2
• 作为产物：
  描述：

  3-Tert-butyl-4-methoxybenzaldehyde dimethyl acetal 以 水 为溶剂， 反应 3.0h， 以leaving 77.5 g of 3-tert-butyl-4-methoxybenzaldehyde (mp. 52°-53 C.), which的产率得到3-叔-丁基-4-甲氧基苯甲醛
  参考文献：
  名称：

  Novel benzaldehyde dialkyl acetals and preparation and use thereof

  摘要：

  公式为##STR1##的苯甲醛二烷基缩醛，其中R是1至4个碳原子的烷基，通过在具有公式ROH的烷醇存在下，对3-叔丁基-4-甲氧基甲苯进行电化学氧化制备，并用作香味或香味中间体。

  公开号：

  US04820389A1

文献信息

• N,N+hu 1 +l SUBSTITUTED PIPERAZINES HAVING COMBINED ANTIAGGREGANT, ANTICOAGULANT AND VASODILATORY ACTIVITY, AND METHOD FOR PRODUCING SAME
  申请人：Veselkina Olga Sergejevna

  公开号：US20130267707A1

  公开（公告）日：2013-10-10

  The invention relates to derivatives of N,N′-substituted piperazines of the general formula (I): where R 1 and R 2 denote linear or branched (C 1 -C 4 )alkyl, linear or branched (C 1 -C 4 )alkoxy, CH 3 C(═O)O or halogen; n=1-5; m=0-3; Z denotes CH 2 , C═O or SO 2 ; X denotes C(═NH)NH 2 , C(═NH)NHC(═NH)NH 2 or CH 2 (CHR 3 ) p CH 2 SO 3 H, where R 3 denotes H, OH, CH 3 C(═O)O or HOSO 2 O and p=0-1; and G denotes low-molecular-weight organic or mineral acid, sodium, potassium or ammonium cations, or water. Said derivatives have antiaggregant, anticoagulant and vasodilatory properties. The invention further relates to a method for producing said derivatives by reacting N-substituted piperazines either with carboxamide amidating agents or salts thereof, or with haloalkyl sulfonic acids or salts thereof in organic solvents or in water in the presence of bases. The compounds may be used for the prophylaxis and treatment of disorders of the hemostatic system.

  该发明涉及一般式（I）的N,N′-取代哌嗪衍生物，其中R1和R2表示线性或支链（C1-C4）烷基，线性或支链（C1-C4）烷氧基，CH3C(═O)O或卤素；n=1-5；m=0-3；Z表示CH2，C═O或SO2；X表示C(═NH)NH2，C(═NH)NHC(═NH)NH2或 (CHR3)p SO3H，其中R3表示H，OH，CH3C(═O)O或HOSO2O，p=0-1；G表示低分子量有机或矿物酸，钠，钾或铵阳离子，或水。所述衍生物具有抗凝、抗凝血和扩血管作用。该发明还涉及一种通过将N-取代哌嗪与羧酰胺化剂或其盐，或卤代烷磺酸或其盐在有机溶剂或水中在碱的存在下反应而制备所述衍生物的方法。这些化合物可用于预防和治疗止血系统疾病。
• Indolinone combinatorial libraries and related products and methods for the treatment of disease
  申请人：Tang Cho Peng

  公开号：US20050197382A1

  公开（公告）日：2005-09-08

  The present invention relates to organic molecules capable of modulating, regulating and/or inhibiting protein kinase signal transduction. Such compounds are useful for the treatment of diseases related to unregulated protein kinase signal transduction, including cell proliferative diseases such as cancer, atherosclerosis, arthritis and restenosis and metabolic diseases such as diabetes. The present invention features indolinone compounds that potently inhibit protein kinases and related products and methods. Inhibitors specific to the FLK protein kinase can be obtained by adding chemical substituents to the 3-[(indole-3-yl)methylene]-2-indolinone, in particular at the 1′ position of the indole ring. Indolinone compounds that specifically inhibit the FLK and platelet derived growth factor protein kinases can harbor a tetrahydroindole or cyclopentano-b-pyrrol moiety. Indolinone compounds that are modified with substituents, particularly at the 5 position of the oxindole ring, can effectively activate protein kinases. This invention also features novel hydrosoluble indolinone compounds that are tyrosine kinase inhibitors and related products and methods.

  本发明涉及有机分子，能够调节、调控和/或抑制蛋白激酶信号转导。这些化合物对于治疗与不受调节的蛋白激酶信号转导相关的疾病非常有用，包括细胞增殖性疾病，如癌症、动脉粥样硬化、关节炎、再狭窄和代谢性疾病，如糖尿病。本发明涉及具有强效抑制蛋白激酶和相关产品以及方法的吲哚酮化合物。特定于FLK蛋白激酶的抑制剂可以通过在吲哚环的1'位置添加化学取代基来获得3-[(吲哚-3-基)亚甲基]-2-吲哚酮。特异性抑制FLK和血小板衍生生长因子蛋白激酶的吲哚酮化合物可以具有四氢吲哚或环戊烯基-β-吡咯基。在氧吲哚环的5位取代基的修饰下，吲哚酮化合物可以有效激活蛋白激酶。本发明还涉及新型水溶性吲哚酮化合物，它们是酪氨酸激酶抑制剂和相关产品和方法。
• Cetp Inhibitors
  申请人：Ali Amjad

  公开号：US20070225365A1

  公开（公告）日：2007-09-27

  Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula 1, A 1 and A 2 are each an aromatic ring, a 5-6-membered heterocyclic ring, an aromatic ring fused to a heterocyclic ring, a phenyl ring fused to a heterocyclic ring, or a cycloalkyl ring.

  公式I的化合物，包括化合物的药物可接受盐，是CETP抑制剂，可用于提高HDL-胆固醇，降低LDL-胆固醇，并用于治疗或预防动脉硬化。在公式1的化合物中，A1和A2分别是芳香环，5-6成员杂环环，芳香环与杂环环融合，苯环与杂环环融合或环状烷基。
• Crf Receptor Antagonists and Methods Relating Thereto
  申请人：Luo Zhiyong

  公开号：US20070287705A1

  公开（公告）日：2007-12-13

  CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm blooded animals, such as stroke. The CRF receptor antagonists of this invention have the following structure (I), including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, Y, Ar, and het are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.

  本发明揭示了CRF受体拮抗剂，其在治疗各种疾病中具有用途，包括治疗温血动物中CRF分泌过多表现的疾病，例如中风。本发明的CRF受体拮抗剂具有以下结构（I），包括立体异构体、前药和其药物可接受的盐，其中R1、R2、R3、Y、Ar和het的定义如下。本发明还揭示了含有CRF受体拮抗剂和药物可接受载体的组合物，以及使用它们的方法。
• CETP INHIBITORS
  申请人：Ali Amjad

  公开号：US20100249024A1

  公开（公告）日：2010-09-30

  Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula 1, A 1 and A2 are each an aromatic ring, a 5-6-membered heterocyclic ring, an aromatic ring fused to a heterocyclic ring, a phenyl ring fused to a heterocyclic ring, or a cycloalkyl ring.

  公式I的化合物，包括该化合物的药用可接受盐，是CETP抑制剂，可用于提高高密度脂蛋白胆固醇，降低低密度脂蛋白胆固醇，并用于治疗或预防动脉硬化。在公式I的化合物中，A1和A2分别是芳香环、5-6元杂环、芳香环与杂环融合、苯环与杂环融合或环状烷基环。